ArticleAACE endocrinology and diabetes
Silent Paralysis: Recurrent Thyrotoxic Periodic Paralysis in a Young Hispanic Male With Graves' Disease.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Thyrotoxic periodic paralysis is a rare, life-threatening complication of thyrotoxicosis, characterized by hypokalemia, hyperthyroidism, and acute muscle weakness. It often occurs in Graves' disease but is not directly linked to the severity or duration of thyrotoxicosis. The objective of this report is to describe a patient with Graves' disease and thyrotoxic periodic paralysis, emphasizing the importance of achieving an euthyroid state, potassium repletion, and the role of β-blockers in management. Case Report: A 23-year-old male with a history of untreated hyperthyroidism presented to the emergency department with palpitations and worsening bilateral lower extremity weakness, culminating in an inability to walk.The patient reported previous episodes of weakness associated with his hyperthyroidism. Physical examination revealed marked muscle weakness and hypertension. Following evaluation, the patient was diagnosed with Graves' disease. He was treated with potassium, magnesium, methimazole, and propranolol, resulting in rapid improvement of his symptoms, and was discharged with outpatient follow-up. Discussion: Thyrotoxic periodic paralysis is a rare manifestation of thyrotoxicosis, which can be precipitated by stressors or medication noncompliance. The pathophysiology involves thyroid hormone-induced shifts in potassium, leading to hypokalemia and muscle weakness. Treatment consists of normalizing thyroid function, managing potassium, and using β-blockers to counteract the overstimulation of muscle cells by thyroid hormones and catecholamines. However, the precise role of β-blockers in preventing attacks requires further investigation. Conclusion: Early diagnosis and treatment of thyrotoxic periodic paralysis, including euthyroid restoration and potassium management, are critical. While β-blockers may be effective in symptom resolution, further studies are needed to clarify their role in preventing attacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.